Display options
Cite
Fabris M, De Vita S, Blasone N, et al. Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights. 2010;1(2):87-94doi: 10.1007/s13317-010-0013-5.
Fabris, M., De Vita, S., Blasone, N., Visentini, D., Pezzarini, E., Pontarini, E., Fabro, C., Quartuccio, L., Mazzolini, S., Curcio, F., & Tonutti, E. (2010). Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto- immunity highlights, 1(2), 87-94. https://doi.org/10.1007/s13317-010-0013-5
Fabris, Martina, et al. "Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab." Auto- immunity highlights vol. 1,2 (2010): 87-94. doi: https://doi.org/10.1007/s13317-010-0013-5
Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, Fabro C, Quartuccio L, Mazzolini S, Curcio F, Tonutti E. Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights. 2010 Nov 04;1(2):87-94. doi: 10.1007/s13317-010-0013-5. eCollection 2010 Nov. PMID: 26000112; PMCID: PMC4389048.
Copy Download .nbib Format: NLM
Share it on

Auto Immun Highlights. 2010 Nov 04;1(2):87-94. doi: 10.1007/s13317-010-0013-5. eCollection 2010 Nov.

Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.

Auto- immunity highlights

Martina Fabris, Salvatore De Vita, Nadia Blasone, Daniela Visentini, Elena Pezzarini, Elena Pontarini, Cinzia Fabro, Luca Quartuccio, Saulle Mazzolini, Francesco Curcio, Elio Tonutti

Affiliations

  1. Clinical Pathology, Azienda Ospedaliero-Universitaria di Udine, P.le S. Maria della Misericordia n.15, 33100 Udine, Italy.
  2. Rheumatology Clinic, Azienda Ospedaliero-Universitaria, Udine, Italy.
  3. Immunopathology and Allergology, Azienda Ospedaliero-Universitaria, Udine, Italy.

PMID: 26000112 PMCID: PMC4389048 DOI: 10.1007/s13317-010-0013-5

Abstract

Rheumatoid arthritis (RA) is characterized by the presence of circulating rheumatoid factor (RF) and anticitrullinated peptide antibodies (ACPA), which are positive in about 70-80% of patients. APCA have a higher specificity and therefore a higher diagnostic power than RF, but are less informative than RF in monitoring the course of the disease in patients under treatment. Recently, it has been reported that the anticitrullinated vimentin (a-MCV) antibody test can identify a particular subgroup of APCA that may be negative for anticyclic citrullinated peptide (a-CCP) antibodies. Concerning RF, the RF IgA isotype has been described as a more specific marker of erosive joint damage than total RF. The aim of our study was to monitor the levels of a-CCP, a-MCV, total RF and RF IgA in the follow-up of patients with RA treated with B-lymphocytedepletive rituximab (RTX), to detect any differences or peculiarities in patterns of these autoantibodies, especially in relation to their potential use as predictive markers of therapeutic response. We studied 30 patients with RA treated with RTX. All patients were previously unresponsive to at least 6 months of therapy with disease-modifying antirheumatic drugs (DMARDs; methotrexate, leflunomide, cyclosporine, chloroquine) and/or at least 6 months of therapy with anti-TNF biologics. The evaluation of response to RTX was made at month +6 using the EULAR criteria (DAS28). a-CCP, a-MCV, total RF and RF IgA were determined at baseline (before the first infusion of RTX) and after 1, 3 and 6 months. In serum samples obtained before treatment two cytokines essential for Blymphocyte proliferation, interleukin 6 (IL-6) and B-lymphocyte stimulator (BLyS) were also determined. In all patients a significant and consistent reduction in all the tested antibodies was found during follow-up, with no differences in respect of the degree of response to RTX. Of note, at baseline, generally a higher titre of all autoantibodies was seen in patients who then showed a better response to RTX. Finally, there were no differences in serum concentrations of IL-6 and BLyS in patients in relation to the presence or absence of the autoantibodies investigated, nor was there any significant correlation between the serum concentrations of the cytokines and the titres of the autoantibodies. Thus, neither a-MCV compared to a- CCP, nor RF IgA compared to routine total RF, provided any additional predictive information in the follow-up of patients with RA treated with RTX.

Keywords: Anticitrullinated peptide antibodies; Antimodified citrullinated vimentin antibodies; Rheumatoid arthritis; Rheumatoid factor; Rituximab

References

  1. Trends Immunol. 2002 Mar;23(3):113-5 - PubMed
  2. Semin Oncol. 2002 Feb;29(1 Suppl 2):2-9 - PubMed
  3. Ann Rheum Dis. 2010 Feb;69(2):345-51 - PubMed
  4. Rheumatology (Oxford). 2009 Dec;48(12):1557-9 - PubMed
  5. Arthritis Rheum. 2003 Apr;48(4):982-92 - PubMed
  6. Arthritis Res Ther. 2009;11(4):R123 - PubMed
  7. Ann Rheum Dis. 2010 Feb;69(2):337-44 - PubMed
  8. Rheumatology (Oxford). 2007 Jan;46(1):37-43 - PubMed
  9. Arthritis Rheum. 2002 Oct;46(10):2673-7 - PubMed
  10. Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1147-52 - PubMed
  11. Lupus. 2006;15(9):570-6 - PubMed
  12. Ann Rheum Dis. 2007 Mar;66(3):302-7 - PubMed
  13. Joint Bone Spine. 2009 May;76(3):248-53 - PubMed
  14. Rheumatology (Oxford). 2009 Aug;48(8):939-43 - PubMed
  15. Ann Rheum Dis. 2004 Sep;63(9):1085-9 - PubMed
  16. Curr Opin Immunol. 2008 Aug;20(4):444-9 - PubMed
  17. Curr Opin Rheumatol. 2010 May;22(3):321-9 - PubMed
  18. Arthritis Rheum. 2009 Dec;60(12):3563-71 - PubMed
  19. Arthritis Rheum. 2008 Jan;58(1):36-45 - PubMed
  20. Ann Rheum Dis. 2003 Feb;62(2):168-71 - PubMed
  21. Arthritis Rheum. 2010 Jan;62(1):44-52 - PubMed
  22. Rheumatol Int. 2011 Jun;31(6):785-94 - PubMed
  23. J Intern Med. 2010 Mar;267(3):260-77 - PubMed
  24. Dig Liver Dis. 2007 Sep;39 Suppl 1:S122-8 - PubMed
  25. Ann Rheum Dis. 2004 Sep;63(9):1079-84 - PubMed
  26. Arthritis Rheum. 2009 Aug;60(8):2232-41 - PubMed
  27. Curr Dir Autoimmun. 2010;11:180-210 - PubMed
  28. Autoimmun Rev. 2010 Jan;9(3):140-3 - PubMed
  29. Scand J Immunol. 2004 Jul-Aug;60(1-2):209-18 - PubMed
  30. Acta Rheumatol Scand. 1959;5:245-62 - PubMed
  31. Arthritis Rheum. 2003 Oct;48(10):2741-9 - PubMed
  32. Mol Diagn Ther. 2010 Feb 1;14(1):43-8 - PubMed
  33. Ann Rheum Dis. 2010 Apr;69(4):730-2 - PubMed
  34. Arthritis Res Ther. 2004;6(2):R142-50 - PubMed
  35. Arthritis Rheum. 2002 Aug;46(8):2029-33 - PubMed
  36. Ann Rheum Dis. 2005 Feb;64(2):299-302 - PubMed
  37. Ann Intern Med. 2007 Jun 5;146(11):797-808 - PubMed
  38. Arthritis Rheum. 1988 Mar;31(3):315-24 - PubMed
  39. Ann Rheum Dis. 2005 Oct;64(10):1510-2 - PubMed
  40. Ann Rheum Dis. 2004 Oct;63(10):1218-21 - PubMed
  41. Clin Chem. 2007 Aug;53(8):1527-33 - PubMed
  42. Arthritis Res Ther. 2008;10(6):R142 - PubMed
  43. Arthritis Rheum. 2007 Aug;56(8):2503-11 - PubMed
  44. Pharmacol Ther. 2010 Mar;125(3):464-75 - PubMed
  45. Neth J Med. 2009 Dec;67(11):362-3 - PubMed
  46. J Exp Med. 2004 Jun 21;199(12):1659-69 - PubMed
  47. J Rheumatol. 2009 Mar;36(3):491-500 - PubMed
  48. Ann Rheum Dis. 2008 Jul;67(7):917-25 - PubMed
  49. Ann Rheum Dis. 2009 Feb;68(2):284-5 - PubMed
  50. Arthritis Res Ther. 2004;6(3):R264-72 - PubMed
  51. Ann Rheum Dis. 2006 Apr;65(4):453-8 - PubMed
  52. Biochem Soc Trans. 2002 Aug;30(4):824-8 - PubMed
  53. Arthritis Rheum. 2002 Feb;46(2):357-65 - PubMed
  54. Arthritis Res Ther. 2006;8 Suppl 2:S2 - PubMed

Publication Types